Navigation Links
NPS Pharmaceuticals to Report 2007 Financial Results
Date:3/6/2008

BEDMINSTER, N.J., March 6 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its 2007 financial results on Thursday, March 13, 2008 post-market. The announcement will be followed by a conference call and webcast at 5:00 p.m. Eastern Time.

To participate in the conference call, dial (866) 510-0708 and use passcode 19613979. International callers may dial (617) 597-5377, using the same passcode. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the NPS website, http://www.npsp.com.

If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 39947050, until midnight Eastern Time, March 28, 2008. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available through the NPS website for the same period.

About NPS Pharmaceuticals

NPS Pharmaceuticals is developing high value specialty therapeutics for gastrointestinal and endocrine disorders. The company is currently advancing two late-stage programs: GATTEX(TM) (teduglutide) is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome and parathyroid hormone 1-84 [rDNA origin] injection is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism. NPS has also completed a Phase 3 osteoporosis study for PREOS(R) (parathyroid hormone 1-84 [rDNA origin] injection). NPS complements its internal programs with strategic partnerships, which include Amgen, GlaxoSmithKline, Kirin, and Nycomed. Additional information is availabl
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ent Highlights Women,s Unmet Needs for HIV Prevent...n Family Planning Methods , , (Para tener a...stellano, vaya al sitio www.preventionnow.net .) ...nternational coalition of organizations that repre...United States is demanding increased access to the...
(Date:12/1/2008)...HONORED FOR CAREER OF SCIENTIFIC DISCOVERY IN MOLE...RNewswire/ -- The Radiologic Society of North Amer... its "Outstanding Researcher of The Year" Award, r...has made original significant contributions to the...h. Dr. Weissleder is Professor at Harvard Medical...
(Date:12/1/2008)... Zimmer Holdings, Inc.,(...ry A. McCaulley has joined the,Company as Preside...ility for,the Company,s activities in the reconst...g and Americas Sales. Mr. McCaulley will report t...ef Executive Officer. , "Jeff has a tremend...
(Date:12/1/2008)...PRNewswire/ -- One of America,s leading plastic,s...aking technique for inner,vaginal lip reduction k...ective. His study is published in the December 20... the official medical journal of the American Soci...er lip) reduction or labioplasty,is the most comm...
Breaking Medicine News(10 mins):Health News:Latin American and U.S. Latina Women Unite to Demand Access to the Female Condom 2Health News:Latin American and U.S. Latina Women Unite to Demand Access to the Female Condom 3Health News:VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year' 2Health News:VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year' 3Health News:Zimmer Holdings Names Jeffery A. McCaulley President, Zimmer Reconstructive 2Health News:Zimmer Holdings Names Jeffery A. McCaulley President, Zimmer Reconstructive 3Health News:Plastic Surgery Journal Shows New Groundbreaking Genital Cosmetic Procedure for Women to be Successful 2
...ntries like Indonesia, the Unjted Nations health b...mised efforts would be made to ensure "fair and eq...s at affordable prices in the event of a pandemic....untries agreed to "timely sharing of viruses" with...
...oon on Monday at a meeting of the U.N. General Ass...S pandemic said he believes it is possible to hal...espite the increasing number of cases worldwide. ...wed pledges and set new targets to provide univers...
...entists has shown that a compound extracted from a...o reduce craving for marihuana, and block its effe...d based National Institute on Drug Abuse found tha...xtract, the rodents lose their hankering for a syn...
...ednesday the possibility that a resident of a prov...cted the lethal H5N1 strain of the bird flu virus,...k of bird flu has hit five provinces in Vietnam. A... lethal H5N1 strain after being hospitalized in se...
Other Medicine News:Health News:WHO Announces Deal on Sharing Bird Flu Virus 2Health News:U.N. Secretary-General Ban Renews Goal To Reverse Spread of HIV by 2015 2Health News:Compound Present in Plant may Help to Curb Craving for Cannabis 2
(Date:11/26/2008)...n., Nov. 26 Children wh...ignificantly increased risk of developing mental i...f a Mayo Clinic study published this month in Ped...demy of Pediatrics. , , The retrospective s...with strabismus (misaligned eyes) and compared the...
(Date:11/25/2008)... most respondents against expanding statin use bro...TLE FALLS, N.J., Nov. 25 JUPITER, ... the cardiovascular risk of healthy patients with ...se in older adults, according to a national poll d...ipants took part in the online poll conducted by m...
(Date:11/25/2008).... 25 CardioVascular,Bio...ounced today that it has,dosed the first patient ...I,clinical trial to treat patients with severe co... the treatment of CORonary heart Disease) trial wi...-controlled doses in approximately 120,patients w...
(Date:11/24/2008)...rms its innovation leadership and long-term commit...N.J., Nov. 24 Schering-P...clinical update on boceprevir, its lead investigat...y in Phase III development. The company believes ...s and best-in-class protease inhibitor for treatin...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9UCSF faculty receive 2413 7M from CIRM for stem cell research 25576 1UCSF faculty receive 2413 7M from CIRM for stem cell research 25576 2UCSF faculty receive 2413 7M from CIRM for stem cell research 25576 3Nurse Practitioner Healthcare Foundation Awards Scholarships to Leaders in Nursing 25574 1Nurse Practitioner Healthcare Foundation Awards Scholarships to Leaders in Nursing 25574 2Nurse Practitioner Healthcare Foundation Awards Scholarships to Leaders in Nursing 25574 3Nurse Practitioner Healthcare Foundation Awards Scholarships to Leaders in Nursing 25574 4VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 1VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 2VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 3VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 4VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 5VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 6VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 7New research on sexual function 25566 1New research on sexual function 25566 2
...ndicate early non-responders unlikely to subsequen...ts, and may benefit,from earlier change in treatme...07 /PRNewswire-FirstCall/,-- New data presented at...Research (ICOSR) suggest that antipsychotic drug,r...ght, and,challenge the current schizophrenia treat...
... Reduced By an Average of More Than Two Hours Per .../PRNewswire/ --,Adding the once daily, investigati...our(TM) Extended-Release Tablets to,Parkinson,s pa...cantly reduced ,off, time, allowing patients to co...of time. ,Off time,describes the return of Parkin...
Other Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5
...d for stone manipulation and removal in the urinar... to retain its shape following extreme torsion. Th...ture by allowing the basket to open at the base of...ign reduces the likelihood of mucosal damage and p...
Used to establish and maintain nephrostomy drainage following pyeloplasty. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is advised; stent must not r
Used for percutaneous placement of a pigtail catheter in the renal pelvis for nephrostomy drainage. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is
The BioPlex 2200 system is a fully automated bead-based multiplexing immunoassay platform that can deliver up to 2200 results per hour. The system will initially include a panel of assays targeting a
Medicine Products: